What the FDA labels say about taking them together
Deferasirox and ticagrelor
Deferasirox's FDA label of January 28, 2026 names ticagrelor in its drug interactions section; the ticagrelor label PlainMeds reads does not name deferasirox. The deferasirox label: “Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4.”
Check it at the source: the deferasirox FDA label on DailyMed (effective January 28, 2026, Novartis Pharmaceuticals Corporation); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).
What does the deferasirox label say about ticagrelor?
Deferasirox label, drug interactionsClosely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].
Source: FDA drug label (Exjade), Novartis Pharmaceuticals Corporation, effective January 28, 2026 (SPL set 3495a70c-870c-4968-940e-8baea152cf85), via openFDA; the full label on DailyMed
What does the ticagrelor label say about deferasirox?
Ticagrelor's label (effective May 7, 2026) does not name deferasirox in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Deferasirox | Ticagrelor | |
|---|---|---|
| Labeled for | n/a | Heart attack and coronary artery disease, Stroke prevention |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.25 per tablet 360 mg tablet | $0.253 per tablet 90 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once